Key clinical point: Durvalumab plus R-CHOP produced complete responses in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL).
Major finding: Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Study details: A phase 2 trial of 43 patients with previously untreated, high-risk DLBCL.
Disclosures: The trial was sponsored by Celgene. Researchers reported relationships with Celgene and other companies.
Nowakowski GS et al. ASCO 2019, Abstract 7520.